RT Journal Article
T1 Mesenchymal Stromal Cells for Treating Steroid-Resistant Acute and Chronic Graft Versus Host Disease: A Multicenter Compassionate Use Experience.
A1 Macías-Sánchez, María Del Mar
A1 Morata-Tarifa, Cynthia
A1 Cuende, Natividad
A1 Cardesa-Gil, Ana
A1 Cuesta-Casas, María Ángeles
A1 Pascual-Cascon, María Jesús
A1 Pascual, Antonia
A1 Martín-Calvo, Carmen
A1 Jurado, Manuel
A1 Perez-Simón, José Antonio
A1 Espigado, Ildefonso
A1 Garzón López, Sebastián
A1 Carmona Sánchez, Gloria
A1 Mata-Alcázar-Caballero, Rosario
A1 Sánchez-Pernaute, Rosario
K1 allogenic hematopoietic stem cell transplantation
K1 cell therapy
K1 graft versus host disease
K1 mesenchymal stromal cells
AB Graft versus host disease (GVHD) is a severe complication after allogenic hematopoietic cell transplantation (HSCT). Several clinical trials have reported the use of mesenchymal stromal cells (MSCs) for the treatment of GVHD. In March 2008, the Andalusian Health Care System launched a compassionate use program to treat steroid-resistant GVHD with MSC. Clinical-grade MSC were obtained under GMP conditions. MSC therapy was administered intravenously in four separate doses of 1 × 106 cells/kg. Sixty-two patients, 45 males (7 children) and 17 females (2 children), received the treatment. Patients had a median age of 39 years (range: 7-66) at the time of the allogenic HSCT. The overall response was achieved in 58.7% of patients with acute (a)GVHD. Two years' survival for aGVHD responders was 51.85%. The overall response for patients with chronic (c)GVHD was 65.50% and the 2-year survival rate for responders was 70%. Age at the time of HSCT was the only predictor found to be inversely correlated with survival in aGVHD. Regarding safety, four adverse events were reported, all recovered without sequelae. Thus, analysis of this compassionate use experience shows MSC to be an effective and safe therapeutic option for treating refractory GVHD, resulting in a significant proportion of patients responding to the therapy.
YR 2022
FD 2022
LK http://hdl.handle.net/10668/19839
UL http://hdl.handle.net/10668/19839
LA en
DS RISalud
RD Apr 10, 2025